Evaluation of the Lifetime Benefits of Metformin and SGLT2 Inhibitors in Type 2 Diabetes Mellitus Patients with Cardiovascular Disease: A Systematic Review and Two-Stage Meta-Analysis.
Hon Jen WongNorman H LinYao Neng TeoNicholas L SynYao Hao TeoChing-Hui SiaPublished in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2024)
In patients with T2DM and CVD, metformin and SGLT2 inhibitors were associated with substantially lower all-cause mortality rates and slightly longer life expectancies than in patients without. Metformin presented an advantage over SGLT2 inhibitors in reducing all-cause mortality.